Dr. Srinivas Sriramula is a tenured Associate Professor in the Department of Pharmacology and Toxicology at the Brody School of Medicine, East Carolina University, where he leads a research program focused on neuroimmune mechanisms underlying cardiovascular and neurodegenerative diseases. His work integrates molecular neuroscience, immunology, and systems physiology to define how chronic inflammatory signaling disrupts brain–body communication and contributes to neuronal vulnerability. As Principal Investigator of a previously funded NIH R01 and recipient of multiple extramural and intramural research awards, Dr. Sriramula has established a research program identifying the kinin B1 receptor as a promising therapeutic target linking neuroinflammation, oxidative stress, and cardiovascular and neurodegenerative pathology.
Dr. Sriramula directs a multidisciplinary laboratory integrating experimental disease models, targeted CNS interventions, and human iPSC-based systems to investigate disease mechanisms and identify therapeutic strategies. His leadership encompasses trainee mentorship, collaborative research initiatives, peer review, and invited scientific presentations. With more than 45 peer-reviewed publications and a strong record of research funding, his current work focuses on neuroimmune signaling pathways contributing to cardiovascular dysfunction, hypertension-induced end organ damage, and neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease.
Dr. Srinivas Sriramula is a tenured Associate Professor in the Department of Pharmacology and Toxicology at the Brody School of Medicine, East Carolina University, where he leads a research program focused on neuroimmune mechanisms underlying cardiovascular and neurodegenerative diseases. His work integrates molecular neuroscience, immunology, and systems physiology to define how chronic inflammatory signaling disrupts brain–body communication and contributes to neuronal vulnerability. As Principal Investigator of a previously funded NIH R01 and recipient of multiple extramural and intramural research awards, Dr. Sriramula has established a research program identifying the kinin B1 receptor as a promising therapeutic target linking neuroinflammation, oxidative stress, and cardiovascular and neurodegenerative pathology.
Dr. Sriramula directs a multidisciplinary laboratory integrating experimental disease models, targeted CNS interventions, and human iPSC-based systems to investigate disease mechanisms and identify therapeutic strategies. His leadership encompasses trainee mentorship, collaborative research initiatives, peer review, and invited scientific presentations. With more than 45 peer-reviewed publications and a strong record of research funding, his current work focuses on neuroimmune signaling pathways contributing to cardiovascular dysfunction, hypertension-induced end organ damage, and neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease.